<DOC>
	<DOCNO>NCT00536263</DOCNO>
	<brief_summary>The purpose study determine efficacy safety two dosage PegIntron treat hepatitis B e antigen ( HBeAg ) positive chronic hepatitis B compare approve dosage , PegIntron 1.0 microgram ( mcg ) /kg give week 24 week . This study compare dosage ( 1 ) 1.5 mcg/kg week 24 week ( 2 ) 1.5 mcg/kg week 48 week approve dosage . All subject follow 24 week treatment end .</brief_summary>
	<brief_title>PegIntron Treatment Chronic Hepatitis B e Antigen-Positive Patients ( P05170/MK-4031-327 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Adults chronic hepatitis B : Serum hepatitis B surface antigen positive least 6 month Serum hepatitis B e antigen positive Serum negative hepatitis B surface e antibody Plasma hepatitis B virus deoxyribonucleic acid ( DNA ) level great 20,000 IU/mL Alanine aminotransferase ( ALT ) 2 10times upper limit normal Compensated liver disease certain minimum hematological serum biochemical criterion Significant hepatic disease etiology hepatitis B virus Antiviral treatment hepatitis within previous 6 month History severe psychiatric disease , especially depression Unstable significant cardiovascular disease Prolonged exposure know hepatotoxin alcohol drug Any condition could interfere subject participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>